The MDA Test to Differentiate of Benign and Malignant Pulmonary Nodules

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-03

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* The purpose of the study is the identification of the efficacy of MDA Test to Differentiate of Benign and Malignant Pulmonary Nodules.
* In this study, the investigators are going to validate the efficacy of the MDA test for diagnosing early lung cancer by comparing results of the pre-surgery MDA test with the post-surgery pathology.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of a Plasma Proteomic Signature for Lung Cancer

NCT01752101

Precancerous Conditions Carcinoma

COMPLETED

Early Adjuvant Diagnosis of Pulmonary Nodules Based on CTC.

NCT06187935

Pulmonary Nodules, Solitary Pulmonary Nodules, Multiple

COMPLETED

Radiomics Multifactorial Biomarker for Pulmonary Nodules

NCT03872362

Lung Neoplasms Carcinoma, Non-Small-Cell Lung Lung Diseases +2 more

COMPLETED

Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy.

NCT03397355

Lung Cancer

UNKNOWN

Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules

NCT03181490

Pulmonary Nodule, Solitary

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Current state-of-the-art lung cancer early screening utilizes low-dose CT scan to identify lung nodules smaller than 3 cm in diameter. However, it's still a clinical challenge to differentiate between malignant and benign nodules.
* This study is being conducted to evaluate the efficacy of the MDA TEST to detect Targeted chromosomal aberrations in circulating abnormal cells by FISH analysis that might be an early indicator of lung cancer. Approximately 200 Pre-surgery adult patients with single pulmonary nodule found by CT scan, will be enrolled in the study. The sample type of MDA test is Peripheral Blood. This study will compare the results of the pre-surgery MDA Test with the post-surgery pathology to determine if the test can detect lung cancer or the lack of lung cancer .
* The results of the test will not be provided to the subject, the investigator and will not be used to diagnose or treat the subject.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Nodule, Solitary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic test

Targeted chromosomal aberrations detection by FISH (MDA TEST).

FISH

Intervention Type DIAGNOSTIC_TEST

Targeted chromosomal aberrations detection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FISH

Targeted chromosomal aberrations detection

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years old or above
* single pulmonary nodule found by CT scan.
* the diameter of the pulmonary nodule is between 5mm to 30mm.
* plan to accept pneumonectomy due to the pulmonary nodule.
* agree to sign informed consent

Exclusion Criteria

* fail to understand or agree to sign informed consent.
* pregnant or lactating women.
* the diameter of the pulmonary nodule is more than 30mm.
* there are 2 or more pulmonary nodules in one single patient.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes